Literature DB >> 6989239

Correction of infantile agranulocytosis (Kostmann's syndrome) by allogeneic bone marrow transplantation.

J M Rappeport, R Parkman, P Newburger, B M Camitta, M J Chusid.   

Abstract

Allogeneic bone marrow transplantation has been unsuccessful as therapy for genetically determined bone marrow disorders. In patients prepared for transplantation with drugs alone long-term hematopoietic engraftment is not achieved due to the overgrowth of the infused donor bone marrow cells by residual recipient hematopoietic stem cells. Utilizing a combination of total body irradiation and antihuman thymocyte serum, the successful eradication of the abnormal hematopoietic stem cells of patients with the Wiskott-Aldrich syndrome and now infantile agranulocytosis has been achieved. Following preparation with total body irradiation and antihuman thymocyte serum a 20 month old patient with infantile agranulocytosis has complete donor hematopoietic and lymphoid engraftment one year after a histocompatible allogeneic bone marrow transplant. Prior to transplantation, this patient had no circulating or bone marrow granulocytes; following transplantation he has normal numbers of circulating granulocytes with normal in vivo and in vitro function. This therapeutic result demonstrates that genetic disorders of myeloid function can be corrected by allogeneic bone marrow transplantation following preparation with total body irradiation and antihuman thymocyte serum, and suggests that infantile agranulocytosis is due to an intrinsic defect of the pluripotent hematopoietic stem cell and not to a micro-environmental defect.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6989239     DOI: 10.1016/0002-9343(80)90312-5

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  8 in total

Review 1.  Bone marrow transplantation. Part I--Allogeneic.

Authors:  N J Chao; K G Blume
Journal:  West J Med       Date:  1989-12

Review 2.  The use of haemopoietic growth factors in blood disorders.

Authors:  I M Hann
Journal:  Arch Dis Child       Date:  1994-12       Impact factor: 3.791

Review 3.  Preparation for bone marrow transplantation.

Authors:  R Parkman
Journal:  Springer Semin Immunopathol       Date:  1984

Review 4.  Displacement bone marrow transplantation for some inborn errors.

Authors:  J R Hobbs
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

Review 5.  Congenital neutropenia: diagnosis, molecular bases and patient management.

Authors:  Jean Donadieu; Odile Fenneteau; Blandine Beaupain; Nizar Mahlaoui; Christine Bellanné Chantelot
Journal:  Orphanet J Rare Dis       Date:  2011-05-19       Impact factor: 4.123

6.  A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia.

Authors:  D C Dale; M A Bonilla; M W Davis; A M Nakanishi; W P Hammond; J Kurtzberg; W Wang; A Jakubowski; E Winton; P Lalezari
Journal:  Blood       Date:  1993-05-15       Impact factor: 22.113

Review 7.  Hematopoetic stem cell transplantation in neutrophil disorders: severe congenital neutropenia, leukocyte adhesion deficiency and chronic granulomatous disease.

Authors:  Ronit Elhasid; Jacob M Rowe
Journal:  Clin Rev Allergy Immunol       Date:  2010-02       Impact factor: 8.667

8.  [Primary and secondary neutropenia].

Authors:  C Zeidler
Journal:  Z Rheumatol       Date:  2013-09       Impact factor: 1.372

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.